Tu Bin, Gao Yanrong, An Xinran, Wang Huiyuan, Huang Yongzhuo
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Acta Pharm Sin B. 2023 May;13(5):1828-1846. doi: 10.1016/j.apsb.2022.09.011. Epub 2022 Sep 23.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been a major health burden in the world. So far, many strategies have been investigated to control the spread of COVID-19, including social distancing, disinfection protocols, vaccines, and antiviral treatments. Despite the significant achievement, due to the constantly emerging new variants, COVID-19 is still a great challenge to the global healthcare system. It is an urgent demand for the development of new therapeutics and technologies for containing the wild spread of SARS-CoV-2. Inhaled administration is useful for the treatment of lung and respiratory diseases, and enables the drugs to reach the site of action directly with benefits of decreased dose, improved safety, and enhanced patient compliance. Nanotechnology has been extensively applied in the prevention and treatment of COVID-19. In this review, the inhaled nanomedicines and antibodies, as well as intranasal nanodrugs, for the prevention and treatment of COVID-19 are summarized.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行已成为全球主要的健康负担。到目前为止，人们已经研究了许多控制COVID-19传播的策略，包括社交距离、消毒方案、疫苗和抗病毒治疗。尽管取得了重大成就，但由于不断出现新的变种，COVID-19仍然是全球医疗系统面临的巨大挑战。开发新的治疗方法和技术以遏制SARS-CoV-2的广泛传播迫在眉睫。吸入给药对肺部和呼吸道疾病的治疗有用，并且能使药物直接到达作用部位，具有降低剂量、提高安全性和增强患者依从性的优点。纳米技术已广泛应用于COVID-19的预防和治疗。在这篇综述中，总结了用于预防和治疗COVID-19的吸入纳米药物和抗体以及鼻内纳米药物。
